ST6GAL1 and prostate carcinoma: Sialylated glycans can be engaged by a broad range of immune cell types to promote immune suppression [105,106], and the upregulation of ST6GAL1 in prostate cancer cells has been shown to promote a shift towards an immunosuppressive M2 macrophage phenotype [52].